Assessment of Grazax® Treatment Compliance

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00293046
Recruitment Status : Completed
First Posted : February 17, 2006
Last Update Posted : September 30, 2008
Information provided by:
ALK-Abelló A/S

Brief Summary:
This trial is performed to assess whether the Grazax® treatment compliance can be improved by use of a compliance device (Memozax®).

Condition or disease Intervention/treatment Phase
Allergy Biological: ALK Grass tablet - use of compliance device Phase 3

Study Type : Interventional  (Clinical Trial)
Enrollment : 500 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Official Title: A Randomised, Parallel-Group, Open, Controlled Phase III Trial Assessing the Treatment Compliance With GRAZAX® in Subjects With Seasonal Grass Pollen Induced Rhinoconjunctivitis
Study Start Date : February 2006
Actual Primary Completion Date : September 2006
Actual Study Completion Date : October 2007

Primary Outcome Measures :
  1. Assessment of treatment compliance by recording of drug accountability

Secondary Outcome Measures :
  1. Recording of adverse events

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Grass pollen induced rhinoconjunctivitis
  • Males and females, 18-65 years of age
  • Positive skin prick test

Exclusion Criteria:

  • Previous treatment with grass pollen allergen

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00293046

Allgergie - Ambulatorium Rennweg
Wien, Austria, 1030
Sponsors and Collaborators
ALK-Abelló A/S
Study Director: Kim Simonsen, MD ALK-Abelló A/S Identifier: NCT00293046     History of Changes
Other Study ID Numbers: GT-10
First Posted: February 17, 2006    Key Record Dates
Last Update Posted: September 30, 2008
Last Verified: September 2008

Keywords provided by ALK-Abelló A/S: